| Drug Name |
Estropipate |
| Drug ID |
BADD_D00836 |
| Description |
Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis. |
| Indications and Usage |
Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
G03CA07; G03CC04 |
| DrugBank ID |
DB04574
|
| KEGG ID |
D00948
|
| MeSH ID |
C009927
|
| PubChem ID |
5284555
|
| TTD Drug ID |
D03IUY
|
| NDC Product Code |
64918-0106; 12875-9998 |
| Synonyms |
estropipate | piperazine estrone sulfate | estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1) | Ogen | Harmogen | Genoral | Harmonet | Ortho-Est |
